Triple therapy takes on tough lung cancer

NCT ID NCT06719700

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether adding two drugs—toripalimab (an immunotherapy) and surufatinib (a targeted therapy)—to standard chemoradiation can help people with limited-stage small cell lung cancer live longer without the disease getting worse. About 47 adults aged 18–75 with stage I–III cancer will receive the combination. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toripalimab and surufatinib combined with chemotherapy and radiation
What this could lead to: If successful, this combination could improve survival for people with limited-stage small cell lung cancer, offering a new treatment option.
What could go wrong: This is an early phase II trial with only 47 participants, so results may not apply to everyone. Adding more drugs also raises the risk of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMORADIOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMORADIOTHERAPY LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) SURUFATINIB TORIPALIMAB

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.